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Background: Several studies reported prognostic value of biomarker in intracerebral hemorrhagic (ICH) but they
are either preliminary observation or inadequately powered to analyse independent contribution of biomarkers
over and above clinical and neuroimaging data.
Objective: To examine whether the biomarker can significantly add to the predictive accuracy of prognosis of ICH.
Method/design: In a multi-centric prospective cohort study, 1020 patients with ICH within 72 hours of onset are
being recruited. After obtaining written informed consent from patients/proxy, venous blood sample (10 ml) is
being collected and analysed for C-reactive protein (CRP) level, S100B, Glial fibrillary acidic protein (GFAP), Troponin,
change in leukocyte count and Copeptin levels. The patients are telephonically followed using stroke scales (Barthel
Index and modified Rankin Scale) at 3, 6, 12 months and 2 years after the recruitment.
Discussion: This protocol will aim at predicting the short term or long term prognosis with the use of clinical,
neuroimaging and biomarkers in order to help clinician to stratify patients for early referral or intervention.
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Stroke has emerged as the second most common cause
of mortality worldwide and a major public health prob-
lem. Intracerebral haemorrhage (ICH) accounts for ap-
proximately 20-30 % of acute strokes in India and is still
associated with a mortality of up to 35–50 % [23]. There
are several fold higher incidence rates of ICH (61/
100,000) in Asian countries [11], including India than in
western countries. It is more common in men than in
women [14]. Overall, the prognosis for ICH is poor:
37-47 % of patients die within the first year after the
event and a substantial proportion of the survivors are* Correspondence: drkameshwarprasad@gmail.com; kp0704@gmail.com
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article, unless otherwise stated.left with serious neurological deficits. About 25 to 30 %
of patients deteriorate within first 24 hours in hospital
because of hematoma growth [12]. Thus, there is an ur-
gent need for a simple diagnostic test which can help in
the hospital management of ICH patients.
Several prospective studies have reported that in-
creased levels of acute inflammatory markers, such as
C-reactive protein (CRP), and white blood cell (WBC)
count are associated with increased risk of death or dis-
ability. Greater changes in leukocyte count over the first
72 hours after admission predicted both short term and
long term worse and functional outcomes after ICH [1].
Blood glucose (BG) represents a novel prognostic
marker in acute ICH, playing a major role in the patho-
genesis of the acute inflammatory response in ICH
patients. The prognostic role of these inflammatoryle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
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.org/publicdomain/zero/1.0/) applies to the data made available in this
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come in patients with ICH is important and biomarkers
might allow the individualization of care by stratifying
risk of reperfusion haemorrhage, predicting relative volume
of penumbral tissue, and providing additional prognostic
information. In this study we propose to investigate the
role of CRP level, serum glial fibrillary acidic protein,
troponin, change in leukocyte count, S100B, copeptin
levels as independent predictors of the neurological
outcome in patients with primary intracerebral
haemorrhage.
Copeptin
Copeptin has emerged as a new diagnostic and prognos-
tic biomarker in various diseases, but its prognostic
value in ICH is still unknown. Its level is high in patients
with ICH. One study suggested that copeptin levels were
higher in patients who died in 30 days than in 30 days
survivors. Its levels were also higher in patients with an
unfavourable clinical outcome at 90 days in ICH [26].
Increase in level of plasma copeptin is an independent
prognostic marker of 1-year mortality, 1-year unfavor-
able outcome and early neurological deterioration [25]
and associated with mortality and outcome in patients
with ICH [26]. Copeptin is a new prognostic marker in
patients with ICH, wrote Zweifel and colleagues, Univer-
sity Hospital, Department of Neurosurgery and also sug-
gested that “if this finding can be confirmed in larger
studies, it might serve as an additional valuable tool for
risk stratification and decision making in ICH patients.”
In this study we will assess the level of copeptin and
identify its relationship with the prediction of outcome
in ICH patients.
Troponin
Cardiac troponin level is being used as a test of choice
for the detection of myocardial injury. One study sug-
gested that in surgically treated ICH, elevated cardiac
troponin levels are predictor of mortality and should be
considered in managing the decisions of ICH [13].
Higher level of troponin on admission is a significant
risk factor for in-hospital mortality in haemorrhagic pa-
tients [3]. Elevated level of cardiac troponin has been as-
sociated with adverse prognosis in patients with acute
neurological diseases. Only few studies have been con-
ducted to know the relation between cTnT and progno-
sis of ICH, but results are not conclusive [17,21]. In this
study, we will identify the relationship between cTnT
and outcome in patients with spontaneous ICH.
S100B
S100B is a member of calcium-mediated low molecular
weight glial protein (approximately 10 kDa). Various com-
binations of subunits (α and β) make up the S100 proteinfamily, which diverge into the hetero- and homodimer
forms of (α and β) subunits. S100B is comprised of the
(α-α, α- β, β-β). The highly specific form is α- β, β-β forms,
to nervous tissue, and is found in abundance in the cerebral
astroglial compartment, peripheral Schwann cells, and
extraneuronally in melanocytes, adipocytes, and chondro-
cytes [9]. The concentration of S100B is 40-fold higher in
CSF than in serum. Serum S100B levels after injury accur-
ately predicts neurological function at discharge after supra-
tentorial ICH in the first 24 h [18]. We hypothesize that
S100B could be useful as a biomarker for ICH patients.
Leukocyte count
After the spontaneous ICH, increase in peripheral leuko-
cytes is an important marker of response of the immune
system and causes the activation of the inflammatory
cascade [2]. This is the most routinely used biomarker
to know the amount of inflammation mounted with
72 hours after the intracerebral haemorrhage. Measure-
ment of leukocyte count after the spontaneous intracere-
bral haemorrhage may accurately reflect the extent of
neuroinflammation. It independently predicts poor func-
tional outcomes in terms of discharge disposition [1].
We hypothesize that change in leukocyte count could be
useful as a biomarker for ICH patients.
C - reactive protein
C-reactive protein (CRP) is an inflammatory protein and
its level rises in response to inflammation in an acute
phase of inflammatory reactions. It binds with phospho-
choline expressed on the surface of dead or dying cells
in order to activate the complement system. It also has a
role in complex modulatory functions. It may directly
participate in enhancing inflammation in cerebral vessels
and brain injury through activation of complement cas-
cade, initiation of leukocyte chemotaxis and expression
of adhesion molecules through a positive feedback
mechanism [15]. It also induces apoptosis through a
caspase-dependent mechanism [4]. Data are limited
regarding the role of CRP in the pathophysiological
mechanisms and predictive outcome after sICH. Higher
levels of CRP are significantly associated with 30-day
death after sICH [7] and an independent predictor of
poor outcome in intracerebral haemorrhage [8]. We
hypothesize that it could be an important predictor of
outcome in ICH patients.
Glial fibrillary acidic protein (GFAP)
Glial fibrillary acidic protein (GFAP) is a member of
cytoskeleton protein family. It is expressed by numerous
cell types of the central nervous system including epen-
dymal cells and astrocyte cells. It helps to maintain
astrocyte mechanical strength, as well as the shape of
the cells. It is evident that GAP is considered to be
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astrocyte response to injury and disease. It is also
involved in promotion of normal blood brain barrier.
One study indicated that serum GFAP may function as a
reliable biomarker for intracerebral haemorrhage in
acute stroke. Increased GFAP levels are associated with
the blood brain barrier injury [20]. GFAP may be useful
as a surrogate marker and may be helpful for manage-
ment of hemorrhagic stroke [12]. We hypothesize that
GFAP is immediately detectable in serum in acute phase
of ICH and could be useful as a biomarker for ICH
patients.
A prediction model based on single or multiple bio-
markers may help in clinical management, if it can pre-
dict haematoma growth or long-term outcome. At
present, there is no single biomarker or panel of bio-
markers that has the level of accuracy or precision to be
useful in clinical practices. A combination of clinical,
neuroimaging and biomarkers may be able to achieve
this objective. The main objectives of the present study
are (i) to determine whether any of the biomarkers
S100B, Copeptin, CRP, Leukocyte count, Troponin, Glial
fibrillary acidic protein are independent predictors of the
neurological outcome in patients with primary intracere-
bral haemorrhage, and (ii) whether any of them (singly








Inclusion and Exclusion criteria
Patients will be eligible if they meet all the inclusion criteria
and none of the exclusion criteria.
Inclusion criteria
Patients will be judged eligible if they have all of the fol-
lowing: (1) Sudden onset of focal neurological deficit or
impairment of consciousness; (2) Age greater than
18 years; (3) CT scan showing parenchymal haematoma
in brain; (4) Admission within 72 hours after the onset
of the qualifying event; (5) Accessibility for follow-up by
telephone (landline or mobile).
Exclusion criteria
Patients meeting the inclusion criteria will be considered
ineligible for the study if they have any one of the fol-
lowing: (1) Suspicion or documented history of a bleed-
ing disorder; (2) History of recent head trauma; (3)History of ingestion of anticoagulant drugs within seven
days of onset of stroke; (4) A documented A-V malfor-
mation; aneurysm or cerebral neoplasm as the under-
lying cause of primary supratentorial intracerebral
haemorrhage; (5) Pre-morbid organ failure or disability
leading to dependence on others for activities of daily
living; (6) Unwillingness to provide written informed
consent (by self or next of kin); (7) Hemorrhagic trans-
formation of cerebral infarct; (8) Concurrent major renal
or hepatic disease; (9) Pregnancy.Centre’s eligibility criteria
(1) Be a Department of Scientific and Industrial Re-
search (DSIR) certified or a medical college or govern-
ment hospital; (2) Admitting at least 5 patients with
stroke per month; (3) Have access to CT scan; computer
and internet; (4) Have access to a laptop and refrigerator
with −80 °C.Consent and Recruitment
Witnessed written informed consent will be requested
from all eligible patients or their next of kin (in case of
patients with aphasia or impaired consciousness). Liter-
ate subjects or their next of kin will be requested to give
their written consent by one of the physician investiga-
tors with a nurse witnessing the consent. Subjects or
their next of kin who are not literate will have the con-
tents of the consent form read out and explained by the
investigator and their left thumb impression will be
taken according to the current practice with a nurse as a
witness. All questions from the subjects or their next of
kin will be answered by the investigator.
Potentially eligible patients will be recruited from the
emergency services and ward of the participating centre.
All potentially eligible patients will undergo emergency
head CT for diagnosis of primary intracerebral haemor-
rhage. All patients with primary intracerebral haemor-
rhage will be admitted and their eligibility will be
assessed by the investigators. Patients suspected to have
aneurysm or arteriovenous malformation will be ex-
cluded unless digital subtraction angiography. A logbook
of all patients screened, those eligible will be maintained.
This log will be used to estimate the proportion of all
potentially eligible patients who enter the study and will
be used to assess the generalizability of study results.Baseline assessment
Standardized forms will be used to record patient
history, general and neurological examination. Clinical,
laboratory and radiological findings to be recorded at
baseline will include:
Table 1 List of Biomarkers to be assayed
S.No Name of Biomarker Source Method of Assessment
1 S100B Plasma ELISA [6]
2 Copeptin Plasma ELISA [10]
3 CRP Serum Immunoturbidimetric
assay [7]
4 Glial fibrillary acidic protein Serum ELISA [19]
5 Leukocyte count Blood Automated cell
counters [5]
6 Troponin Serum ELISA [21]
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Age, Sex, History of hypertension, diabetes, smoking and
family history of stroke or coronary artery disease, Treat-
ment history for hypertension and diabetes, if known to
have one or both of these, Time of onset of the stroke,
Blood pressure at the time of recruitment, Glasgow
Coma Scale (GCS) score at the time of recruitment,
Barthel index (BI) score at the time of recruitment,
National Institute of Health Stroke Scale (NIHSS) and
ICH Score.
B. Radiological assessment
Site and volume of haematoma and any midline shift as
determined on CT scan, Intraventricular extension of
the haematoma as determined by CT scan, CT scans will
be uploaded on the day of recruitment using software to
be installed by AIIMS neuro-radiology department. The
scans will be viewed for quality on the same day, and if
not satisfactory, repeat CT will be done within hours.
C. Biomarker Assay and Sample transportation
After the written informed consent of patient/relatives
venous blood sample (10 ml) will be collected in a spe-
cific serum vacutainer and EDTA coated vial. For serum
collection it will be left standing at room temperature
for 30 min until clotted. It will then undergo centrifuga-
tion at 3000 rpm for 15 min, after which the serum will
be separated into two equal aliquots in serum containing
vials. Both aliquots will be stored at −80 °C. EDTA tubes
will be centrifuged for plasma separation and stored
at −80 °C until analysis. It will be packed within a month
at participating centres and transferred to Principal
Centre (AIIMS) for the biomarker analysis. Prior to ship-
ment the serum samples will be removed from the −80 °C
refrigerator and will be placed inside one of two identical
reusable thermal insulated pouches. A single frozen ice
pack, gel pack and dry ice will be placed inside one of the
two insulated pouches and sealed. Samples will be trans-
ferred by using standard courier service to the AIIMS by
priority overnight delivery. Sample will be used to assay
the biomarker levels using available methods as men-
tioned in Table 1.
Sample Size
As this study involves multiple variables (11 clinical, 03
neuroimaging and 06 biomarkers), we plan to use prog-
nostic modelling. According to Harrell et al. [16] a stable
and replicable model will require 20 events per variable.
As the outcome events in ICH over six months has a
frequency of approximate 50 % [24], and 23 variables are
planned to be examined, we need 920 patients with
complete follow up. Adjusting this for 10 % loss to fol-
low up, yields a sample size of 1020.Patient management
All subjects will receive standard medical therapy con-
sisting of maintenance of adequate airway, fluids and
electrolyte balance, and good pulmonary and cardiac
function. Nasogastric feeding will be instituted in uncon-
scious patients. Patients who experience a seizure at any
time since onset of the stroke will be given a loading
dose of an anticonvulsant intravenously (usually pheny-
toin 15–20 mg/kg body weight i.v. push) followed by a
maintenance dose (usually phenytoin 5 mg/kg divided
over a period of three time a day i.v. push) until recovery
of consciousness when oral administration of the same
dose will be continued for six months. The dose and the
drug will be adjusted to minimize the side-effects. Severe
hypertension (defined as systolic BP more than 200 mg
Hg and diastolic BP more than 120 mm Hg) will be
treated with diuretics and/or ACE inhibitors so as to
keep systolic BP between 160–200 mm Hg and diastolic
BP between 100–110 mm Hg. Corticosteroids, glycerol
or antithrombotics will not be used. Hyperventilation
will be used to control intracranial pressure especially
when signs of brain herniation develop. The medical
management of all patients will be carried out by a team
of neurologists and neuroanaesthetists in the intensive
care unit settings according to National guidelines [22].
Patients meeting the criteria according to the National
guideline will be operated. All interventions adminis-
tered to the patients will be recorded and documented
for trial purposes.
In-hospital follow-up
All subjects will be assessed daily by the neurologist in-
vestigators with the help of neurology residents. CT scan
will be repeated between 24 to 48 hours to detect
haematoma growth. Serum chemistry and blood gases
will be monitored daily for unconscious patients. Other
investigations will be done when clinically indicated. A
ward physiotherapist will see each subject twice a week
and implement an appropriate physiotherapy plan.
Nurses will provide nursing care to all subjects regularly.
All subjects will be observed in the hospital for a mini-
mum period of 30 days post-inclusion with the
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the hospital early.
Outpatient follow up
Central telephonic follow-up will be done at three
months, six months and then on annual basis till the
end of the study. This data will be used to study the fre-
quency and determination of recurrent stroke in this
population on long term basis (such data is not yet avail-
able from India).
Strategies to minimize losses to follow-up
All the patients will be followed centrally by telephone.
For this, two to five telephone numbers (both mobile
and landline) will be noted from the patients or his/her
relatives at the time of recruitment. A research worker
trained and certified in modified Rankin scale (mRS) will
administer the scale to all patients (or his representative)
from AIIMS, blinded to the baseline clinical or neuroim-
aging scores or level of biomarkers.
On failure to contact, the worker will attempt to ob-
tain a new contact number from the relatives or other
contacts and administer the scale.
Outcomes and their measurement
The primary endpoint will be death at 30 days. Glasgow
Outcome Scale (GOS) will be used to determine the
functional recovery at 30 days. Good clinical outcome
will be considered if GOS score would be 4 and 5 and
poor outcome if score would be 1–3.
A research worker trained and certified in modified
Rankin scale will administer the scale at three months
and six months to all patients blinded to the baseline
clinical or neuroimaging scores or result of biomarkers.
Barthel index at three months and six months post-
inclusion will be measured centrally by blinded and
trained research worker by telephone in a binary scale as
‘independent’ or ‘dead/dependent’. ‘Independent’ is
defined as the Barthel index score of 60 or more. Surviving
subjects who do not achieve this are classified as
‘dependent’. Favorable clinical outcome: defined as any of
the following:
 A score of 0 to 3 on mRS at 180 days
 A Barthel Index score of 60 to 100 at 180 days
Statistical Method
After data clearing and rectification bivariate analysis
will be done to determine association between the pre-
dictor variable and outcome. Continuous variables will
be described by mean and SD and categorical variables
by percentage. Association between biomarkers and
radiological score would be done by linear regression
methods. For examining independence of theassociation, logistic (for dichotomous dependent vari-
able) or cox regression (for time to event variable) will
be used. For determining accuracy and precision, prog-
nostic models will be developed using standard methods
and prediction rules will be framed.
Discussion
This study will aim at predicting the poor short term or
long term prognosis with the use of clinical neuroimag-
ing and biomarkers such as CRP, GFAP, troponin,
change in leukocyte count, S100B and copeptin in order
to help clinicians to stratify patients for early referral/
intervention.
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